Does hydroxychloroquine combat COVID-19? A timeline of evidence.
作者信息
Alia Erisa, Grant-Kels Jane M
机构信息
Dermatology Department, University of Connecticut, Farmington, Connecticut.
Dermatology Department, University of Connecticut, Farmington, Connecticut.
出版信息
J Am Acad Dermatol. 2020 Jul;83(1):e33-e34. doi: 10.1016/j.jaad.2020.04.031. Epub 2020 Apr 10.
Abstract
摘要
相似文献
1
Does hydroxychloroquine combat COVID-19? A timeline of evidence.羟氯喹能对抗新冠病毒吗？证据时间表。
J Am Acad Dermatol. 2020 Jul;83(1):e33-e34. doi: 10.1016/j.jaad.2020.04.031. Epub 2020 Apr 10.
2
The coronavirus outbreak could make it quicker and easier to trial drugs.冠状病毒的爆发可能会使药物试验更快、更容易。
Nature. 2020 Jun;582(7811):172. doi: 10.1038/d41586-020-01524-0.
3
Regulators split on antimalarials for COVID-19.监管机构在用于治疗新冠肺炎的抗疟疾药物问题上存在分歧。
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
4
Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.用于治疗新冠肺炎的氯喹/羟氯喹引发室性心律失常的风险：是否应该使用该药？
Indian Heart J. 2020 Mar-Apr;72(2):131-132. doi: 10.1016/j.ihj.2020.04.006. Epub 2020 Apr 27.
5
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).关于氯喹/羟氯喹治疗 2019 年冠状病毒病（COVID-19）的最新情况。
Biosci Trends. 2020 May 21;14(2):156-158. doi: 10.5582/bst.2020.03072. Epub 2020 Apr 13.
6
[Not Available].[不可用]。
Rev Med Suisse. 2020 Apr 15;16(690):756-757.
7
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Apr 8;16(689):704-705.
8
Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.COVID-19大流行期间的紧急使用授权：羟氯喹用于疫苗授权和批准的经验教训。
JAMA. 2020 Oct 6;324(13):1282-1283. doi: 10.1001/jama.2020.16253.
9
Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.2019年冠状病毒病大流行期间羟氯喹短缺对系统性红斑狼疮患者的潜在后果
J Rheumatol. 2020 Jun 1;47(6):787-790. doi: 10.3899/jrheum.200395. Epub 2020 Apr 8.
10
Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.COVID-19时代严格的随机对照试验实施
Am J Trop Med Hyg. 2020 Jun;102(6):1154-1155. doi: 10.4269/ajtmh.20-0262.
引用本文的文献
1
Hydroxychloroquine-induced acute generalized exanthematous pustulosis with HLA-typing.羟氯喹诱导的急性泛发性脓疱性皮病伴HLA分型
Pharmacogenomics. 2024;25(14-15):569-572. doi: 10.1080/14622416.2024.2430167. Epub 2024 Nov 18.
2
Acute generalized exanthematous pustulosis due to hydroxichloroquine.羟氯喹所致急性泛发性发疹性脓疱病
Dermatol Ther. 2022 Jul;35(7):e15520. doi: 10.1111/dth.15520. Epub 2022 Apr 23.
3
Efficacy of early use of remdesivir: a systematic review of subgroup analysis.瑞德西韦早期使用的疗效：亚组分析的系统评价。
Rev Esp Quimioter. 2022 Jun;35(3):249-259. doi: 10.37201/req/154.2021. Epub 2022 Mar 17.
4
Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis.氯喹和羟氯喹治疗住院COVID-19患者的疗效：一项荟萃分析。
Future Virol. 2021 Nov. doi: 10.2217/fvl-2021-0119. Epub 2021 Dec 3.
5
Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study.2019冠状病毒病（COVID-19）患者的羟氯喹血清浓度：一项回顾性研究。
Forensic Sci Res. 2021 Aug 19;6(3):215-217. doi: 10.1080/20961790.2021.1936896. eCollection 2021.
6
Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉新冠肺炎患者使用羟氯喹/氯喹的回顾性队列研究。
BMC Infect Dis. 2021 Aug 12;21(1):805. doi: 10.1186/s12879-021-06477-x.
7
COVID-19: The experience from Iran.新型冠状病毒肺炎：来自伊朗的经验
Clin Dermatol. 2021 Jan-Feb;39(1):23-32. doi: 10.1016/j.clindermatol.2020.12.009. Epub 2020 Dec 15.
8
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
9
Recent biotechnological advances as potential intervention strategies against COVID-19.作为对抗新冠病毒潜在干预策略的近期生物技术进展。
3 Biotech. 2021 Feb;11(2):41. doi: 10.1007/s13205-020-02619-1. Epub 2021 Jan 9.
10
Risk of COVID-19 infection among lupus erythematosus patients and rheumatoid arthritis patients: a retrospective study in Hubei, China.红斑狼疮患者和类风湿关节炎患者中新型冠状病毒肺炎感染风险：中国湖北的一项回顾性研究
Eur J Dermatol. 2020 Dec 1;30(6):751-753. doi: 10.1684/ejd.2020.3926.
本文引用的文献
1
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.仓促下结论？有关羟氯喹治疗 COVID-19 的快速报告和结果传播及其后果。
Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30.
2
Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence.新冠疫情：尽管缺乏证据，仍有600万剂羟氯喹被捐赠给美国。
BMJ. 2020 Mar 23;368:m1166. doi: 10.1136/bmj.m1166.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.COVID-19：建议检查羟氯喹预防感染和进展的效果。
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. doi: 10.1093/jac/dkaa114.
5
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
6
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?氯喹抗冠状病毒的抗病毒作用的新见解：对 COVID-19 有何期待？
Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.
7
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
8
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.氯喹和羟氯喹作为对抗新型冠状病毒肺炎的现有武器。
Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.
9
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破：磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
10
Chloroquine for the 2019 novel coronavirus SARS-CoV-2.氯喹用于2019新型冠状病毒SARS-CoV-2。
Int J Antimicrob Agents. 2020 Mar;55(3):105923. doi: 10.1016/j.ijantimicag.2020.105923. Epub 2020 Feb 15.
Zotero 插件